Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.162
Filtrar
1.
Front Endocrinol (Lausanne) ; 15: 1368225, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39381443

RESUMEN

Objective: The aim of this study was to develop and validate a machine learning-based model to predict the development of impaired fasting glucose (IFG) in middle-aged and older elderly people over a 5-year period using data from a cohort study. Methods: This study was a retrospective cohort study. The study population was 1855 participants who underwent consecutive physical examinations at the First Affiliated Hospital of Soochow University between 2018 and 2022.The dataset included medical history, physical examination, and biochemical index test results. The cohort was randomly divided into a training dataset and a validation dataset in a ratio of 8:2. The machine learning algorithms used in this study include Extreme Gradient Boosting (XGBoost), Support Vector Machines (SVM), Naive Bayes, Decision Trees (DT), and traditional Logistic Regression (LR). Feature selection, parameter optimization, and model construction were performed in the training set, while the validation set was used to evaluate the predictive performance of the models. The performance of these models is evaluated by an area under the receiver operating characteristic (ROC) curves (AUC), calibration curves and decision curve analysis (DCA). To interpret the best-performing model, the Shapley Additive exPlanation (SHAP) Plots was used in this study. Results: The training/validation dataset consists of 1,855 individuals from the First Affiliated Hospital of Soochow University, yielded significant variables following selection by the Boruta algorithm and logistic multivariate regression analysis. These significant variables included systolic blood pressure (SBP), fatty liver, waist circumference (WC) and serum creatinine (Scr). The XGBoost model outperformed the other models, demonstrating an AUC of 0.7391 in the validation set. Conclusions: The XGBoost model was composed of SBP, fatty liver, WC and Scr may assist doctors with the early identification of IFG in middle-aged and elderly people.


Asunto(s)
Algoritmos , Glucemia , Ayuno , Humanos , Femenino , Masculino , Estudios Retrospectivos , Persona de Mediana Edad , Glucemia/análisis , Anciano , Factores de Riesgo , Ayuno/sangre , Aprendizaje Automático , Intolerancia a la Glucosa/sangre , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/epidemiología , Estado Prediabético/diagnóstico , Estado Prediabético/sangre , Estado Prediabético/epidemiología
2.
Clin Exp Dent Res ; 10(6): e70023, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-39400977

RESUMEN

OBJECTIVES: The aim of this study was to investigate whether periodontal condition is associated with the development of impaired glucose tolerance (IGT). MATERIAL AND METHODS: This study was based on a subpopulation of a cohort of persons born in 1935 and living in Oulu, Finland, on October 1, 1990. The participants were normoglycemic (no previously diagnosed diabetes mellitus and a 2-h oral glucose tolerance test [OGTT] blood glucose < 7.8 mmol/L) in the baseline examinations (1990-1992) and had fasting blood glucose < 7.0 mmol/L in the follow-up examinations (2007-2008) (n = 225). The outcome was IGT on follow-up, measured by a blood glucose level of ≥ 7.8 mmol/L after OGTT. The exposure was the periodontal condition at baseline categorized into four groups: 0, 1-6, ≥ 7 sites with deepened (≥ 4 mm) periodontal pockets, and edentulousness. RESULTS: A total of 23% of the participants developed IGT. The adjusted incidence rate ratios with 95% confidence intervals (CI) for dentate participants with 1-6 sites and ≥ 7 sites with deepened periodontal pockets, and edentate participants (reference category dentate participants without deepened periodontal pockets) were 1.5 (95% CI, 0.6-4.0), 1.8 (95% CI, 0.7-4.4), and 1.6 (95% CI, 0.6-4.0), respectively. CONCLUSIONS: Poor periodontal condition may predispose individuals to IGT; however, further studies on this matter are warranted.


Asunto(s)
Intolerancia a la Glucosa , Prueba de Tolerancia a la Glucosa , Humanos , Intolerancia a la Glucosa/epidemiología , Intolerancia a la Glucosa/sangre , Intolerancia a la Glucosa/diagnóstico , Femenino , Masculino , Estudios de Seguimiento , Persona de Mediana Edad , Finlandia/epidemiología , Anciano , Enfermedades Periodontales/epidemiología , Enfermedades Periodontales/complicaciones , Enfermedades Periodontales/sangre , Glucemia/análisis , Glucemia/metabolismo , Bolsa Periodontal/epidemiología , Factores de Riesgo , Incidencia , Boca Edéntula/epidemiología
3.
Diabetes Res Clin Pract ; 216: 111831, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39168186

RESUMEN

AIM: To explore how introduction of the lower WHO gestational diabetes (GDM) glucose criteria in Sweden affected prediabetes/type-2-diabetes (T2D) incidence two years postpartum. METHODS: Women included in the PREvention of PostPartum (PREPP) diabetes study were diagnosed with GDM according to EASD 1991 criteria (GDMOLD; n = 93) or only WHO 2013 criteria (GDMWHO; n = 174). Both groups were further stratified by BMI, and BMI-matched normoglycemic pregnancy controls were included (n = 88). Postpartum assessments included oral glucose tolerance tests (OGTT) and anthropometric measurements. RESULTS: There was a higher postpartum incidence of T2D in GDMOLD versus GDMWHO (P < 0.001). Despite similar BMI, GDMOLD exhibited higher fasting and OGTT glucose levels, lower fat-free-mass, and hip circumference compared to GDMWHO. In normal-weight women, both GDM groups displayed higher HOMA-IR and lower fat-free-mass compared to controls, with GDMOLD additionally showing lower HOMA-ß, slower insulin release during OGTT, and worse glucose tolerance than GDMWHO. Among obese women, the main differences were lower fat-free-mass and hip circumference in GDMOLD. CONCLUSION: The lower glucose cut-offs during pregnancy resulted in lower postpartum incidence of T2D, irrespective of BMI. Fat-free-mass emerged as a key determinant in glucose levels across BMI categories, while lower beta-cell function played a significant role in normal-weight women.


Asunto(s)
Glucemia , Diabetes Mellitus Tipo 2 , Diabetes Gestacional , Prueba de Tolerancia a la Glucosa , Humanos , Diabetes Gestacional/diagnóstico , Diabetes Gestacional/sangre , Diabetes Gestacional/epidemiología , Femenino , Embarazo , Adulto , Suecia/epidemiología , Glucemia/análisis , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/sangre , Periodo Posparto , Organización Mundial de la Salud , Índice de Masa Corporal , Incidencia , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/epidemiología , Intolerancia a la Glucosa/sangre , Estado Prediabético/diagnóstico , Estado Prediabético/sangre
4.
Cardiovasc Diabetol ; 23(1): 295, 2024 Aug 10.
Artículo en Inglés | MEDLINE | ID: mdl-39127733

RESUMEN

BACKGROUND: A compromised cardiac autonomic function has been found in subjects with insulin resistance related disorders such as obesity, impaired glucose tolerance (IGT) and type 2 diabetes and confers an increased risk of adverse cardiovascular outcomes. Growing evidence indicate that 1 h plasma glucose levels (1hPG) during an oral glucose tolerance test (OGTT) ≥ 155 mg/dl identify amongst subjects with normal glucose tolerance (NGT) a new category of prediabetes (NGT 1 h-high), harboring an increased risk of cardiovascular organ damage. In this study we explored the relationship between 1 h post-load hyperglycemia and cardiac autonomic dysfunction. METHODS: Presence of cardiac autonomic neuropathy (CAN) defined by cardiovascular autonomic reflex tests (CARTs) and heart rate variability (HRV), assessed by 24-h electrocardiography were evaluated in 88 non-diabetic subjects subdivided on the basis of OGTT data in: NGT with 1 h PG < 155 mg/dl (NGT 1 h-low), NGT 1 h-high and IGT. RESULTS: As compared to subjects with NGT 1 h-low, those with NGT 1 h-high and IGT were more likely to have CARTs defined CAN and reduced values of the 24 h time domain HVR parameters including standard deviation of all normal heart cycles (SDNN), standard deviation of the average RR interval for each 5 min segment (SDANN), square root of the differences between adjacent RR intervals (RMSSD), percentage of beats with a consecutive RR interval difference > 50 ms (PNN50) and Triangular index. Univariate analyses showed that 1hPG, but not fasting and 2hPG, was inversely associated with all the explored HVR parameters and positively with CARTs determined presence of CAN. In multivariate regression analysis models including several confounders we found that 1hPG was an independent contributor of HRV and presence of CAN. CONCLUSION: Subjects with 1hPG ≥ 155 mg/dl have an impaired cardiac autonomic function.


Asunto(s)
Sistema Nervioso Autónomo , Glucemia , Prueba de Tolerancia a la Glucosa , Frecuencia Cardíaca , Hiperglucemia , Humanos , Estudios Transversales , Masculino , Femenino , Persona de Mediana Edad , Sistema Nervioso Autónomo/fisiopatología , Glucemia/metabolismo , Hiperglucemia/fisiopatología , Hiperglucemia/sangre , Hiperglucemia/diagnóstico , Adulto , Factores de Tiempo , Biomarcadores/sangre , Enfermedades del Sistema Nervioso Autónomo/fisiopatología , Enfermedades del Sistema Nervioso Autónomo/diagnóstico , Enfermedades del Sistema Nervioso Autónomo/sangre , Corazón/inervación , Corazón/fisiopatología , Electrocardiografía Ambulatoria , Estado Prediabético/fisiopatología , Estado Prediabético/diagnóstico , Estado Prediabético/sangre , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/fisiopatología , Intolerancia a la Glucosa/sangre , Factores de Riesgo
5.
PLoS Med ; 21(7): e1004419, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38980837

RESUMEN

BACKGROUND: The association between years of non-diabetes status after diagnosis of impaired glucose tolerance (IGT) and the risk of long-term death and cardiovascular outcomes needed to be clarified. METHODS AND FINDINGS: In this post hoc analysis, we included 540 individuals with IGT who participated in the original Da Qing Diabetes Prevention Study (DQDPS). In the DQDPS, all participants were diagnosed with IGT by a 75 g oral glucose tolerance test and randomized to intervention or control groups with a 6-year lifestyle intervention trial. After the completion of the trial, death, cardiovascular events, and microvascular complications were monitored over a 30-year follow-up. In this post hoc analysis, the Cox analysis assessed the extended risk of these outcomes in individuals who either remained non-diabetes status or progressed to diabetes at the end of 2, 4, and 6 years after diagnosis of IGT. In all participants, the difference in the cumulative incidence rate of the outcomes between the diabetes and non-diabetes group gradually increased over 30 years. Compared with the diabetes group, a significantly lower risk of all-cause death (hazard ratio [HR]: 0.74; 95% confidence interval [CI]: 0.57 to 0.97, p = 0.026), cardiovascular events (HR: 0.63; 95% CI: 0.49 to 0.82, p < 0.001), and microvascular complications (HR: 0.62; 95% CI: 0.45 to 0.86, p = 0.004) first emerged in individuals who remained non-diabetes at the 4 years visit, whereas the significant risk reduction in cardiovascular death was first observed at the end of 6 years (HR: 0.56; 95% CI: 0.39 to 0.81, p = 0.002) after adjustment for age, sex, smoking status, BMI, systolic blood pressure, blood glucose, total cholesterol, intervention, and medications (including insulin plus oral hypoglycaemics, antihypertensives, and lipid-lowering agents). The results in the original intervention group alone were similar to the whole group. The main limitations of our study are the limited number of participants and the sole ethnicity of the Chinese population. CONCLUSIONS: In this study, we observed that maintaining several years of non-diabetes status after IGT diagnosis was associated with a significant reduction in long-term risk of death and vascular complications, and for most of these outcomes, maintaining at least 4 years of non-diabetes status may be needed to achieve a significant risk reduction.


Asunto(s)
Intolerancia a la Glucosa , Humanos , Masculino , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/complicaciones , Femenino , Persona de Mediana Edad , Prueba de Tolerancia a la Glucosa , China/epidemiología , Anciano , Enfermedades Cardiovasculares/mortalidad , Enfermedades Cardiovasculares/prevención & control , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/epidemiología , Factores de Riesgo , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/diagnóstico , Adulto
6.
J Cyst Fibros ; 23(5): 857-862, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38942723

RESUMEN

BACKGROUND: Adult people living with Cystic Fibrosis (CF) undergo annual screening for CF-related diabetes. These tests represent a burden and can lead to undesirable effects resulting in low adherence. The objectives of this study were to 1) compare gold-standard in-hospital oral glucose tolerance testing (OGTT) with at-home options, and 2) evaluate acceptability of at-home options. METHODS: A total of 34 adults living with CF undertook 3 types of OGTTs in standardized conditions within two weeks: 1) in a hospital using a 75 g glucose beverage, 2) at home with the same glucose beverage, and 3) at home using a standardized quantity of candy. Glucose levels were measured prior to the OGTT, after 1 and 2 hours. Concordance of glucose measurement, side effects and general appreciation were assessed across the three options. RESULTS: Mean blood glucose was comparable among the three tests. Glucose tolerance categorization (normal, impaired glucose tolerance, or diabetes) was concordant with the hospital reference test in 59 % of participants for the glucose beverage and 75 % for the candies. Side effects were mild with all types of OGTTs, and 94 % of participants preferred the home options. Among the at-home OGTTs, the glucose beverage was preferred to the candy option. CONCLUSIONS: Home-based OGTT could be an alternative to gold standard hospital-based OGTT testing, improving adherence to annual testing and reducing costs. However, the discrepancy between various OGTT testing methods could lead to diagnosis dilemma. This approach should be tested on a larger sample size.


Asunto(s)
Fibrosis Quística , Diabetes Mellitus , Estudios de Factibilidad , Prueba de Tolerancia a la Glucosa , Tamizaje Masivo , Humanos , Fibrosis Quística/diagnóstico , Fibrosis Quística/sangre , Prueba de Tolerancia a la Glucosa/métodos , Masculino , Femenino , Adulto , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/sangre , Tamizaje Masivo/métodos , Glucemia/análisis , Glucemia/metabolismo , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/sangre , Reproducibilidad de los Resultados
7.
Diabetes Res Clin Pract ; 212: 111718, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38796080

RESUMEN

BACKGROUND: We compared performance of high 1-hour PG level, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) in predicting type 2 diabetes in a longitudinal community-based cohort of Hong Kong Chinese. METHODS: Between 2001 and 2003, 472 adults aged 18-55 years without diabetes underwent 75-gram oral glucose tolerance test (OGTT). Between 2012 and 2014, progression to diabetes was ascertained by reviewing medical records or repeating OGTT and HbA1c. We defined high 1-hour PG as PG ≥ 8.6 mmol/L at 1-hour. RESULTS: In this cohort, 23.5% had normal glucose tolerance and high 1-hour PG, 10.0% had isolated IGT, 4.2% had isolated IFG. Over 12-year follow-up, 9.3% developed type 2 diabetes. In logistic regression, high 1-hour PG was associated with progression to type 2 diabetes with adjusted odds ratio (95% CI) of 4.20 (1.60, 12.40), independent of IFG, IGT and other clinical variables. Areas under ROC (95% CI) for type 2 diabetes were similar between 1-hour (0.84 [0.78, 0.89], 2-hour (0.79 [0.72, 0.86]) and fasting PG (0.79 [0.71, 0.86]). CONCLUSION: High 1-hour PG identified young Chinese with 5-fold increased risk of type 2 diabetes independent of other intermediate hyperglycaemia status and clinical factors. 1-hour PG is similar to fasting and 2-hour PG in predicting type 2 diabetes.


Asunto(s)
Glucemia , Diabetes Mellitus Tipo 2 , Prueba de Tolerancia a la Glucosa , Humanos , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/diagnóstico , Hong Kong/epidemiología , Masculino , Adulto , Femenino , Persona de Mediana Edad , Glucemia/análisis , Glucemia/metabolismo , Intolerancia a la Glucosa/sangre , Intolerancia a la Glucosa/epidemiología , Intolerancia a la Glucosa/diagnóstico , Adulto Joven , Adolescente , Ayuno/sangre , Progresión de la Enfermedad , Pueblos del Este de Asia
8.
J Diabetes Complications ; 38(4): 108703, 2024 04.
Artículo en Inglés | MEDLINE | ID: mdl-38430625

RESUMEN

BACKGROUND: Cystic fibrosis related diabetes (CFRD) is commonly associated with declining lung function and nutritional status. We aimed to evaluate the pulmonary impact of early glucose abnormalities by using 2-h standard oral glucose tolerance testing (OGTT) and continuous glucose monitoring (CGM) in people with cystic fibrosis (PwCF). METHODS: PwCF aged ≥10 years old without known CFRD were included in a five-year prospective multicentre study. Annual evaluation of nutritional status, lung function, OGTT and CGM was set up. Associations between annual rate changes (Δ) in lung function, ΔFEV1 (forced expiratory volume in 1 s) percentage predicted (pp) and ΔFVC (forced vital capacity) pp., and annual rate changes in OGTT or CGM variables were estimated with a mixed model with a random effect for subject. RESULTS: From 2009 to 2016, 112 PwCF (age: 21 ± 11 years, BMI (body mass index) z-score: -0.55 ± 1.09, FEV1pp: 77 ± 24 %, 2-h OGTT glucose: 122 ± 44 mg/dL, AUC (area under curve) >140 mg/dL: 1 mg/dL/day (0.2, 3.0) were included. A total of 428 OGTTs and 480 CGMs were collected. The participants presented annual decline of FVCpp and FEV1pp at -1.0 % per year (-1.6, -0.4), p < 0.001 and - 1.9 % per year (-2.5, -1.3), p < 0.001 respectively without change in BMI z-score during the study. Variation of two-hour OGTT glucose was not associated with declining lung function, as measured by ΔFEV1pp (p = 0.94) and ΔFVCpp (p = 0.90). Among CGM variables, only increase in AUC >140 mg/dL between two annual visits was associated with a decrease in ΔFVCpp (p < 0.05) and ΔFEV1pp (p < 0.05). CONCLUSIONS: This prospective study supports the fact that early glucose abnormalities revealed by CGM predict pulmonary function decline in PwCF, while 2-h standard OGTT glucose is not associated with pulmonary impairment.


Asunto(s)
Fibrosis Quística , Diabetes Mellitus , Intolerancia a la Glucosa , Humanos , Niño , Adolescente , Adulto Joven , Adulto , Fibrosis Quística/complicaciones , Fibrosis Quística/diagnóstico , Estudios Prospectivos , Glucemia , Intolerancia a la Glucosa/complicaciones , Intolerancia a la Glucosa/diagnóstico , Glucosa , Automonitorización de la Glucosa Sanguínea , Monitoreo Continuo de Glucosa , Diabetes Mellitus/diagnóstico , Pulmón
9.
Diabetes Obes Metab ; 26(6): 2329-2338, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38488254

RESUMEN

AIM: To evaluate whether 1-hour plasma glucose (1hPG) can be a comparable measurement to 2-hour plasma glucose (2hPG) in identifying individuals at high risk of developing diabetes. METHODS: A total of 1026 non-diabetic subjects in the Da Qing IGT and Diabetes Study were included and classified according to baseline postload 1hPG. The participants were followed up and assessed at 6-, 20- and 30year follow-up for outcomes including diabetes, all-cause and cardiovascular mortality, cardiovascular disease (CVD) events, and microvascular disease. We then conducted a proportional hazards analysis in this post hoc study to determine the risks of developing type 2 diabetes and its complications in a '1hPG-normal' group (1hPG <8.6 mmol/L) and a '1hPG-high' group (≥8.6 mmol/L). The predictive values of 1hPG and 2hPG were evaluated using a time-dependent receiver-operating characteristic (ROC) curve. RESULTS: Compared with the 1hPG-normal group, the 1hPG-high group had increased risk of diabetes (hazard ratio [HR] 4.45, 95% CI 3.43-5.79), all-cause mortality (HR 1.46, 95% CI 1.07-2.01), CVD mortality (HR 1.84, 95% CI 1.16-2.95), CVD events (HR 1.39, 95% CI 1.03-1.86) and microvascular disease (HR 1.70, 95% CI: 1.03-2.79) after adjusting for confounders. 1hPG exhibited a higher area under the ROC curve (AUC) for predicting diabetes than 2hPG during the long-term follow-up (AUC [1hPG vs. 2hPG]: 10 years: 0.86 vs. 0.84, p = 0.08; 20 years: 0.88 vs. 0.87, p = 0.04; 30 years: 0.85 vs. 0.82, p = 0.009). CONCLUSIONS: Elevated 1hPG level (≥8.6 mmol/L) was associated with increased risk of developing type 2 diabetes and its long-term complications, and could be considered as a suitable measurement for identifying individuals at high risk of type 2 diabetes.


Asunto(s)
Glucemia , Diabetes Mellitus Tipo 2 , Valor Predictivo de las Pruebas , Humanos , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/sangre , Masculino , Femenino , Persona de Mediana Edad , Glucemia/análisis , Glucemia/metabolismo , Estudios de Seguimiento , China/epidemiología , Prueba de Tolerancia a la Glucosa , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/mortalidad , Intolerancia a la Glucosa/sangre , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/complicaciones , Adulto , Complicaciones de la Diabetes/sangre , Complicaciones de la Diabetes/epidemiología , Anciano , Angiopatías Diabéticas/epidemiología , Angiopatías Diabéticas/sangre , Angiopatías Diabéticas/diagnóstico , Angiopatías Diabéticas/prevención & control , Angiopatías Diabéticas/mortalidad , Curva ROC
10.
J Cyst Fibros ; 23(4): 616-624, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38458829

RESUMEN

BACKGROUND: Despite translational evidences suggesting that cystic fibrosis-related abnormal glucose tolerance (CF-related AGT) may begin early in life and is known to be associated with increased morbidity and mortality, current guidelines recommend screening for AGT only from 10 years of age, thus missing the opportunity for early detection and intervention. METHODS: A systematic review and meta-analysis (PROSPERO number: CRD42021282516) was conducted on studies that reported data on the prevalence of AGT or its subtypes in CF populations. Pooled proportions, risk, and odds ratios with 95 % confidence intervals (CI) were calculated. One-stage dose-response random-effect meta-analysis was used to assess the effect of age on CF-related diabetes (CFRD). RESULTS: The quantitative analysis included 457 studies and data from 520,544 patients. Every third child with CF (chwCF) (0.31 [95 % CI 0.25-0.37]) and every second adult with CF (awCF) (0.51 [95 % CI 0.45-0.57]) were affected by AGT. Even in the 5-10 years of age subgroup, the proportion of AGT was 0.42 [95 % CI 0.34-0.51]. The prevalence of prediabetes remained unchanged (impaired glucose tolerance in chwCF:0.14 [95 % CI 0.10-0.18]) vs. awCF:0.19 [95 % CI 0.14-0.25]), whereas the proportion of CFRD increased with age (0-5: 0.005 [95 % CI 0.0001-0.15]; 5-10: 0.05 [95 % CI 0.01-0.27]; 10-18: 0.11 [95 % CI 0.08-0.14]; >18 years of age: 0.27 [95 % CI 0.24-0.30]). CONCLUSION: CF-related AGT is common under 10 years of age. Our study suggests considering earlier AGT screening, starting from 5 years of age. This highlights the imperative for additional research for guideline adjustments and provides the opportunity for early intervention.


Asunto(s)
Fibrosis Quística , Intolerancia a la Glucosa , Niño , Humanos , Edad de Inicio , Fibrosis Quística/complicaciones , Fibrosis Quística/epidemiología , Fibrosis Quística/terapia , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/epidemiología , Diabetes Mellitus/etiología , Diabetes Mellitus/prevención & control , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/epidemiología , Intolerancia a la Glucosa/etiología , Intolerancia a la Glucosa/prevención & control , Preescolar , Adulto , Adolescente , Adulto Joven
11.
J Clin Res Pediatr Endocrinol ; 16(3): 264-270, 2024 09 05.
Artículo en Inglés | MEDLINE | ID: mdl-38488037

RESUMEN

Objective: Disorders of glucose metabolism in children with obesity are less common than in adults. There is also evidence that they may be transient. The aims of this study were to determine the prevalences of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and type 2 diabetes mellitus (DM2) and its reversibility in pediatric patients with obesity and to define the factors determining the reversibility of prediabetes or progression to diabetes. Methods: Retrospective analysis included of young patients with obesity. Patients presented and were treated between 2000-2022 at a single center. Results: The study included 573 (316 girls; 55.15%) Caucasian patients with median body mass index (BMI) Z-score of 3.95 (range 2.0-9.9) and median age 13.9 (2.9-17.1) years old. OGTT results were normal in 90.8% (n=520) and signs of prediabetes occurred in 9.2% (n=53); IFG 17%, IGT 88.7%, DM 0%. Among those who underwent OGTT twice (n=53), impaired glucose regulation was present in 9.3% (n=5) (IFG 40%, IGT 80%, DM 0%) at baseline and in 14.8% subject (n=8) (IFG 25%, IGT 50%, DM 25%) at follow-up after lifestyle modification only. After 12-36 months of follow up, in those with a history of IGT, 60% reverted to normal glucose tolerance, while IFG and IGT persisted in 20% and 20%, respectively, and none progressed to DM. The risk factors for progression of glucose metabolism disorders were increase of BMI Z-score, higher insulin levels and elevated homeostatic model assessment-insulin resistance. Conclusion: IFG and IGT are common in pediatric patients with obesity, while the progression to DM2 is rare. Disorders of glucose metabolism have reversible character.


Asunto(s)
Glucemia , Diabetes Mellitus Tipo 2 , Intolerancia a la Glucosa , Prueba de Tolerancia a la Glucosa , Hiperglucemia , Obesidad Infantil , Estado Prediabético , Humanos , Femenino , Masculino , Niño , Adolescente , Estudios Retrospectivos , Obesidad Infantil/metabolismo , Obesidad Infantil/diagnóstico , Obesidad Infantil/sangre , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/metabolismo , Estado Prediabético/diagnóstico , Estado Prediabético/metabolismo , Estado Prediabético/sangre , Glucemia/metabolismo , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/epidemiología , Preescolar , Hiperglucemia/diagnóstico , Hiperglucemia/metabolismo , Prevalencia , Índice de Masa Corporal , Progresión de la Enfermedad
13.
Nutr Metab Cardiovasc Dis ; 34(6): 1448-1455, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38499452

RESUMEN

BACKGROUND AND AIMS: The World Health Organization (WHO) updated its cardiovascular disease (CVD) risk prediction charts in 2019 to cover 21 global regions. We aimed to assess the performance of an updated non-lab-based risk chart for people with normoglycaemia, impaired fasting glucose (IFG), and diabetes in Eastern Sub-Saharan Africa. METHODS AND RESULTS: We used data from six WHO STEPS surveys conducted in Eastern Sub-Saharan Africa between 2012 and 2017. We included 9857 participants aged 40-69 years with no CVD history. The agreement between lab- and non-lab-based charts was assessed using Bland-Altman plots and Cohen's kappa. The median age of the participants was 50 years (25-75th percentile: 44-57). The pooled median 10-year CVD risk was 3 % (25-75th percentile: 2-5) using either chart. According to the estimation, 7.5 % and 8.4 % of the participants showed an estimated CVD risk ≥10 % using the non-lab-based chart or the lab-based chart, respectively. The concordance between the two charts was 91.3 %. The non-lab-based chart underestimated the CVD risk in 57.6 % of people with diabetes. In the Bland-Altman plots, the limits of agreement between the two charts were widest among people with diabetes (-0.57-7.54) compared to IFG (-1.75-1.22) and normoglycaemia (-1.74-1.06). Kappa values of 0.79 (substantial agreement), 0.78 (substantial agreement), and 0.43 (moderate agreement) were obtained among people with normoglycaemia, IFG, and diabetes, respectively. CONCLUSIONS: Given limited healthcare resources, the updated non-lab-based chart is suitable for CVD risk estimation in the general population without diabetes. Lab-based risk estimation is suitable for individuals with diabetes to avoid risk underestimation.


Asunto(s)
Biomarcadores , Glucemia , Enfermedades Cardiovasculares , Diabetes Mellitus , Factores de Riesgo de Enfermedad Cardiaca , Valor Predictivo de las Pruebas , Organización Mundial de la Salud , Humanos , Persona de Mediana Edad , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/diagnóstico , Medición de Riesgo , Femenino , Masculino , Adulto , Anciano , Glucemia/metabolismo , Biomarcadores/sangre , Diabetes Mellitus/epidemiología , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/sangre , Reproducibilidad de los Resultados , Pronóstico , África del Sur del Sahara/epidemiología , Técnicas de Apoyo para la Decisión , Estudios Transversales , Factores de Tiempo , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/sangre , Intolerancia a la Glucosa/epidemiología
14.
BMJ Open Diabetes Res Care ; 12(1)2024 Feb 19.
Artículo en Inglés | MEDLINE | ID: mdl-38373805

RESUMEN

INTRODUCTION: Type 2 diabetes is preventable in subjects with impaired glucose tolerance based on 2-hour plasma glucose (2hPG) during 75 g oral glucose tolerance test (OGTT). We incorporated routine biochemistry to improve the performance of a non-invasive diabetes risk score to identify individuals with abnormal glucose tolerance (AGT) defined by 2hPG≥7.8 mmol/L during OGTT. RESEARCH DESIGN AND METHODS: We used baseline data of 1938 individuals from the community-based "Better Health for Better Hong Kong - Hong Kong Family Diabetes Study (BHBHK-HKFDS) Cohort" recruited in 1998-2003. We incorporated routine biochemistry in a validated non-invasive diabetes risk score, and evaluated its performance using area under receiver operating characteristics (AUROC) with internal and external validation. RESULTS: The AUROC of the original non-invasive risk score to predict AGT was 0.698 (95% CI, 0.662 to 0.733). Following additional inclusion of fasting plasma glucose, serum potassium, creatinine, and urea, the AUROC increased to 0.778 (95% CI, 0.744 to 0.809, p<0.001). Net reclassification improved by 31.9% (p<0.001) overall, by 30.8% among people with AGT and 1.1% among people without AGT. The extended model showed good calibration (χ2=11.315, p=0.1845) and performance on external validation using an independent data set (AUROC=0.722, 95% CI, 0.680 to 0.764). CONCLUSIONS: The extended risk score incorporating clinical and routine biochemistry can be integrated into an electronic health records system to select high-risk subjects for evaluation of AGT using OGTT for prevention of diabetes.


Asunto(s)
Diabetes Mellitus Tipo 2 , Intolerancia a la Glucosa , Humanos , Intolerancia a la Glucosa/diagnóstico , Diabetes Mellitus Tipo 2/diagnóstico , Glucemia , Prueba de Tolerancia a la Glucosa , Factores de Riesgo
15.
Diabetes Res Clin Pract ; 208: 111124, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38309533

RESUMEN

AIMS: The diagnosis of cystic fibrosis-related diabetes (CFRD) faces several challenges. We propose a novel screening algorithm to alleviate the burden of cystic fibrosis (CF). METHODS: Through a retrospective cross-sectional single-centre study, HbA1c and HOMA2 indices were assessed in multiple models as alternative diagnostic tools from OGTT data. We sought to establish specific thresholds for CFRD screening with oral glucose tolerance test (OGTT) as gold standard. We evaluated various straightforward or sequential approaches, in terms of diagnostic accuracy while also quantify the potential reduction in OGTTs through these different methods. RESULTS: HOMA indices were recovered in 72 patients. We devised a composite index that combines HbA1c and HOMA-B: Diabetes Predicting Index in cystic fibrosis (DIPIc) = (HbA1c(%) × 3.455) - (HOMA-B(%) ×  0.020) - 19.294. This index yields the highest screening accuracy according to receiver-operating characteristics curves. Using a stepwise algorithm that incorporates DIPIc decreases the requirement for annual OGTTs. A CFRD exclusion cutoff less than -1.7445 (sensitivity 98 %), in conjunction with a CFRD diagnostic threshold greater than 0.4543 (specificity 98 %) allows for 71 % OGTT sparing. CONCLUSION: The composite index DIPIc is a suitable, less invasive screening method for CFRD, which enables to avoid many OGTTs.


Asunto(s)
Fibrosis Quística , Diabetes Mellitus , Intolerancia a la Glucosa , Humanos , Prueba de Tolerancia a la Glucosa , Hemoglobina Glucada , Fibrosis Quística/complicaciones , Fibrosis Quística/diagnóstico , Glucemia , Estudios Retrospectivos , Estudios Transversales , Diabetes Mellitus/diagnóstico , Intolerancia a la Glucosa/diagnóstico
16.
Pediatr Hematol Oncol ; 41(3): 198-210, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38269620

RESUMEN

Glycemic abnormalities are a frequent finding in pediatric oncological patients, both during treatment and after its discontinuation. Moreover, impaired glucose tolerance (IGT), impaired fasting glycemia (IFG) and diabetes mellitus (DM) are not rarely diagnosed in non-oncological hematological diseases. To explore the current pediatric Italian approach to the diagnosis and the management of the glycemic alterations in this clinical setting and, thus, to identify and enforce current clinical needs, we submitted an online 23-items survey to all the Italian Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) centers, and surveys were descriptively analyzed. Thirty-nine AIEOP centers were involved in the study. In 2021, among 75278 children and adolescents affected by an oncological or a hematological disease, 1.2 and 0.65% developed DM, while IGT or IFG were widespread in 2.3 and 2.8%, respectively. The main causes of DM were the use of corticosteroids in patients with cancer and the iron overload in patients with thalassemia. Venous fasting plasma glycemia was the most used tool to detect glycemic abnormalities. The performance of oral glucose tolerance test (OGTT) was extremely limited, except when IFG occurred. Despite the diagnosis of DM, ∼45% of patients with cancer and 30% of patients with one hematological disease did not receive an appropriate treatment. In the other cases, insulin was the drug of first choice. Emerging technologies for diabetes care (glucose sensors and insulin pumps) are not largely used yet. The results of our study support the standardization of the care of the glycemic abnormalities during or after onco-hematologic diseases in the pediatric age. Despite the scarce data in pediatric literature, proper guidelines are needed.


Asunto(s)
Diabetes Mellitus , Intolerancia a la Glucosa , Enfermedades Hematológicas , Insulinas , Neoplasias , Estado Prediabético , Adolescente , Humanos , Niño , Glucemia , Diabetes Mellitus/diagnóstico , Intolerancia a la Glucosa/diagnóstico , Enfermedades Hematológicas/epidemiología , Enfermedades Hematológicas/terapia , Homeostasis
17.
Metab Syndr Relat Disord ; 22(2): 151-159, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38190317

RESUMEN

Aims: The present study aimed to clarify the relationships between novel and traditional anthropometric indices and insulin sensitivity (SI) in young and middle-aged Japanese persons with normal glucose tolerance (NGT), and middle-aged Japanese persons with NGT and glucose intolerance. Methods: Plasma glucose and insulin levels were measured in 1270 young (age <40 years) and 2153 middle-aged persons with NGT (n = 1531) and glucose intolerance (n = 622) during a 75-g oral glucose tolerance test. Height (Ht), weight, and waist circumference (WC) were measured. The body mass index (BMI), WC, and the WC/Ht ratio were used as traditional anthropometric indices. A body shape index (ABSI) and the body roundness index (BRI) were calculated as novel indices. Indices of SI (Matsuda index and 1/homeostasis model assessment of insulin resistance) were calculated and compared with anthropometric indices. Results: The ABSI showed a weak correlation with SI indices in all groups. The BRI showed almost the same correlation with SI indices as the BMI, WC, and WC/Ht in all groups. The inverse correlation between each of the anthropometric indices other than ABSI and SI indices was weak in young persons, at 0.16-0.27 (Spearman's ρ values), but strong in middle-aged persons, at 0.38-1.00. On receiver-operating characteristic (ROC) curve analysis for detection of insulin resistance, the ABSI had a lower area under the ROC curve (AUC) than the other anthropometric indices, and the BRI and the WC/Ht ratio showed similar AUCs. The AUCs for the BRI and WC/Ht ratio were the highest in middle-aged men with NGT and glucose intolerance. Conclusions: The BRI, not the ABSI, was better correlated with SI in young and middle-aged Japanese persons. The BRI and WC/Ht ratio were comparable in their correlations with SI and the detection of insulin resistance in the participants of the present study.


Asunto(s)
Intolerancia a la Glucosa , Resistencia a la Insulina , Masculino , Persona de Mediana Edad , Humanos , Adulto , Índice de Masa Corporal , Obesidad/diagnóstico , Factores de Riesgo , Intolerancia a la Glucosa/diagnóstico , Japón , Antropometría , Circunferencia de la Cintura
18.
Metab Syndr Relat Disord ; 22(3): 199-206, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38190491

RESUMEN

Aims: The aim of the present study is to estimate insulin resistance (IR) using clinically available parameters except for serum insulin or C-peptide concentration to overcome the limitation of homeostasis model assessment of IR (HOMA-IR), which has been widely used in clinical practice. Patients and Methods: Fifty-two admitted patients with type 2 diabetes or impaired glucose tolerance were enrolled, and steady state plasma glucose (SSPG) method and cookie meal tolerance test were performed together with fasting blood sampling and anthropometric measurements. Insulin sensitivity measured by SSPG was estimated as glucose clearance corrected by the excretion of glucose into urine (C-GC). Results: Log-transformed (C-GC) was negatively correlated with fasting plasma glucose (FPG), log (Fasting triglyceride: TG), log (Fasting TG/Fasting high-density lipoprotein cholesterol: HDLC), and their area under the curves (AUCs). Fasting and AUC-HDLC was positively and fasting free fatty acid (FFA) was negatively correlated with log (C-GC). Body fat (%) was negatively correlated with log (C-GC). Multiple regression analysis on log (C-GC) as an outcome variable revealed that FPG, log (AUC-TG/AUC-HDLC), body fat (%), and fasting FFA were selected as significant predictive variables and contributed to log (C-GC) by 60% (adjusted R2). Replacing log (AUC-TG/AUC-HDLC) with its fasting value, log (Fasting TG/Fasting HDLC), this model still showed a strong contribution to log (C-GC) by 57% (adjusted R2). These contributions were stronger than those in log (HOMA-IR) (52.5%), log (Fasting C-peptide) (45.7%) to log (C-GC). Conclusions: It is plausible that our estimation for IR without the inclusion of plasma insulin concentration can be applied in Japanese patients whose HOMA-IR is not appropriately available. The model using fasting values is less complicated and could be the best way for the estimation of IR.


Asunto(s)
Diabetes Mellitus Tipo 2 , Intolerancia a la Glucosa , Resistencia a la Insulina , Humanos , Diabetes Mellitus Tipo 2/diagnóstico , Intolerancia a la Glucosa/diagnóstico , Glucosa , Glucemia , Péptido C , Japón/epidemiología , Insulina , Ayuno , Triglicéridos , Ácidos Grasos no Esterificados , Tejido Adiposo
19.
Diab Vasc Dis Res ; 21(1): 14791641241228156, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38228168

RESUMEN

PURPOSE: To evaluate the effects of chromium (Cr) and magnesium (Mg) ions on metabolic profiles, inflammation, and oxidative stress with impaired glucose tolerance (IGT) and insulin resistance (IR). METHODS: 120 individuals with IGT and IR were randomly divided into four groups treated with (1) chromium, (2) magnesium, (3) chromium and magnesium or (4) placebo. Metabolic and inflammatory indicators were measured at baseline and after 3 months intervention. RESULTS: Comparison among groups showed that fasting plasma glucose (FPG), 2 h post glucose (2hPPG), fasting insulin (FINS) and homeostatic model assessment for insulin resistance (HOMA-IR) in Cr + Mg group were significantly decreased compared with the other three groups (p < .05), and high density lipoprotein (HDL-c) levels were higher. 8-iso prostaglandin F2 alpha (8-iso-PGF2a) decreased in Cr, Mg, and Cr + Mg groups compared with placebo (p < .05), and 8-iso-PGF2a decreased in Cr + Mg groups compared with Cr group and Mg groups (p > .05). Intra-group comparison showed that the levels of FPG, 2hPPG and FINS in Cr + Mg group were significantly decreased after intervention (p < .05), and FINS in Mg group was significantly decreased (p < .01). The levels of HDL-c and triacylglycerol (TG) in Cr + Mg group were significantly improved (p < .05). The level of HDL-c in Mg group was significantly improved compared with baseline (p < .05). Compared with baseline, high-sensitivity C-reactive protein (hsCRP) levels in Cr + Mg group and Mg group were significantly decreased (p < .05). CONCLUSIONS: The co-supplementation of Cr and Mg improves glycemic and lipid levels and reduces the inflammatory response and oxidative stress profiles of individuals with impaired glucose tolerance and insulin resistance.


Asunto(s)
Intolerancia a la Glucosa , Resistencia a la Insulina , Humanos , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/tratamiento farmacológico , Magnesio/uso terapéutico , Cromo/uso terapéutico , Glucemia/metabolismo , Insulina , Inflamación/diagnóstico , Inflamación/tratamiento farmacológico , Suplementos Dietéticos/efectos adversos , Estrés Oxidativo , Metaboloma
20.
Reprod Sci ; 31(3): 773-778, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-37816990

RESUMEN

This study aimed to investigate the use of leptin as a marker for gestational diabetes by analyzing any correlation between serum leptin levels versus oral glucose tolerance tests (at 24 to 28 weeks of pregnancy) and increased body weight (during pregnancy). A total of 110 female cases (81 pregnant and 29 non-pregnant) were included in the study. The 81 pregnant cases were divided into 3 groups according to their oral glucose tolerance test results. A chi-square test was used for categorical variables. The distribution of numerical variables was tested with the Shapiro-Wilk test. ANOVA and a post-hoc Bonferroni test was used for parametric data. Kruskal-Wallis variance analysis was used for non-parametric data. The Mann-Whitney U-test was used for pairwise comparisons. Spearman correlation analysis and multivariate regression analysis were performed for the evaluation of the correlation analysis between the parameters. Oral glucose tolerance test results were compared with leptin levels with a cut-off value of 11.43 for leptin. The ROC curve demonstrated an 83.3% sensitivity and 72.1% specificity for leptin. Leptin may play a role in the pathophysiology of gestational diabetes mellitus. However, the relationship between leptin levels and maternal weight gain during pregnancy is still unknown.


Asunto(s)
Diabetes Gestacional , Intolerancia a la Glucosa , Embarazo , Femenino , Humanos , Diabetes Gestacional/diagnóstico , Intolerancia a la Glucosa/diagnóstico , Mujeres Embarazadas , Leptina , Estudios de Casos y Controles , Estudios Prospectivos , Glucemia/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA